Pacira BioSciences, Inc. (PCRX)
Market Cap | 1.06B |
Revenue (ttm) | 681.75M |
Net Income (ttm) | 70.47M |
Shares Out | 46.55M |
EPS (ttm) | 1.45 |
PE Ratio | 15.68 |
Forward PE | 7.48 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 9,097,658 |
Open | 28.25 |
Previous Close | 28.46 |
Day's Range | 20.52 - 28.63 |
52-Week Range | 20.52 - 40.16 |
Beta | 0.87 |
Analysts | Strong Buy |
Price Target | 47.40 (+108.44%) |
Earnings Date | Jul 31, 2024 |
About PCRX
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and sup... [Read more]
Full Company ProfileFinancial Performance
In 2023, PCRX's revenue was $674.98 million, an increase of 1.22% compared to the previous year's $666.82 million. Earnings were $41.96 million, an increase of 163.72%.
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for PCRX stock is "Strong Buy." The 12-month stock price forecast is $47.4, which is an increase of 108.44% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/a/f/conf18-2453450.jpg)
Pacira BioSciences to Participate in Fireside Chat at the 2024 Jefferies Global Healthcare Conference
TAMPA, Fla., May 30, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 2024 Jefferies Global Healthcare C...
![](https://cdn.snapi.dev/images/v1/s/w/press16-2423690.jpg)
Pacira BioSciences, Inc. Announces Pricing of $250.0 Million Aggregate Principal Amount of 2.125% Convertible Senior Notes due 2029
TAMPA, Fla., May 10, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today announced the pricing of $250.0 million aggregate principal amount of convertible senior notes due 2029 (the...
![](https://cdn.snapi.dev/images/v1/f/p/press4-2419285.jpg)
Pacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior Notes
TAMPA, Fla., May 08, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today announced that it intends to offer, subject to market and other conditions, $250.0 million aggregate princip...
![](https://cdn.snapi.dev/images/v1/k/v/press20-2416020.jpg)
Pacira BioSciences Reports First Quarter 2024 Financial Results and Announces $150 Million Share Repurchase program
-- Conference call today at 4:30 p.m. ET -- TAMPA, Fla., May 07, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management a...
![](https://cdn.snapi.dev/images/v1/j/l/conf8-2414473.jpg)
Pacira BioSciences to Participate in Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference
TAMPA, Fla., May 07, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 2024 RBC Capital Markets Global He...
![](https://cdn.snapi.dev/images/v1/k/4/conf10-2399464.jpg)
Pacira to Report First Quarter 2024 Financial Results on Tuesday May 7, 2024
TAMPA, Fla., April 30, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its first quarter financial results after the close of the U.S. markets on Tu...
![](https://cdn.snapi.dev/images/v1/s/q/press2-2351828.jpg)
Pacira BioSciences to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
TAMPA, Fla., April 02, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 23rd Annual Needham Virtual Heal...
![](https://cdn.snapi.dev/images/v1/k/t/press20-2321776.jpg)
Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee
-- PCRX-201 is the first gene therapy product candidate to receive RMAT designation for osteoarthritis -- -- Designation supported by encouraging preliminary data from 72-patient Phase 1 study --
![](https://cdn.snapi.dev/images/v1/o/a/conf4-2310663.jpg)
Pacira BioSciences to Participate in Fireside Chat at the Barclays 26th Annual Global Healthcare Conference
TAMPA, Fla., March 06, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the Barclays 26th Annual Global Heal...
![](https://cdn.snapi.dev/images/v1/8/n/press16-2300864.jpg)
Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial Results
— Record revenues of $675 million in 2023 — — Full-year GAAP net income of $42 million and adjusted EBITDA of $214 million — — EXPAREL surpasses the 14 million patient mark — — Conference call today a...
![](https://cdn.snapi.dev/images/v1/n/a/conf9-2288314.jpg)
Pacira to Report 2023 Financial Results on Thursday February 29, 2024
TAMPA, Fla., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its fourth quarter and year ended December 31, 2023 financial results before t...
![](https://cdn.snapi.dev/images/v1/3/6/press6-2278026.jpg)
Pacira Announces Publication of Pivotal Study of EXPAREL as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy
– Findings demonstrate significant reduction in pain and opioid consumption through 96 hours versus active comparator –
![](https://cdn.snapi.dev/images/v1/d/i/press11-2264246.jpg)
Pacira BioSciences Awarded Brand Pharmaceuticals Agreement With Premier, Inc.
TAMPA, Fla., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc., (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, has been...
![](https://cdn.snapi.dev/images/v1/r/x/press8-2255847.jpg)
G.O.A.T. Bowl I Registration Open to 4 Additional Pickleball Teams
High Demand for Participation in Pickleball's Big Game on Feb. 9 in Las Vegas Leads to Tournament's Expansion to 24 Teams and Signing of New Sponsors LAS VEGAS , Feb. 1, 2024 /PRNewswire/ -- Paradise ...
![](https://cdn.snapi.dev/images/v1/r/z/press15-2217414.jpg)
Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2023 Revenues
TAMPA, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today rep...
![](https://cdn.snapi.dev/images/v1/q/n/conf8-2214500.jpg)
Pacira BioSciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
TAMPA, Fla., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 42nd Annual J.P. Morgan Healthcare Conference at 8:15 AM PT (11:15 AM...
![](https://cdn.snapi.dev/images/v1/a/6/im-09753645size1777777777777778width800-2208256.jpg)
20 favorite small-cap stocks for 2024 among Wall Street analysts
The 2023 stock-market rally has been led by the “Magnificent Seven” companies, which have driven an accelerating upward trend for the large-cap benchmark S&P 500. Shares of smaller and medium-sized co...
![](https://cdn.snapi.dev/images/v1/w/w/press7-2204763.jpg)
Pacira Appoints Frank D. Lee as Chief Executive Officer
-- Transformational Leader Brings Three Decades of Global Experience in Pharmaceutical and Biotechnology Product Development and Commercialization -- -- Paul J. Hastings Named Chair of the Board --
![](https://cdn.snapi.dev/images/v1/d/h/press14-2151998.jpg)
Pacira Announces FDA Approval of Expanded EXPAREL Label to Include Two Additional Nerve Block Indications
— EXPAREL is the only FDA-approved single-dose regional analgesic to safely demonstrate four days of superiority versus bupivacaine in two clinical studies —
![](https://cdn.snapi.dev/images/v1/w/m/press7-2143742.jpg)
Pacira BioSciences to Participate in Fireside Chat at Two Healthcare Conferences in November
TAMPA, Fla., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the following two healthcare conferen...
![](https://cdn.snapi.dev/images/v1/u/a/press11-2135813.jpg)
Pacira BioSciences Reports Third Quarter 2023 Financial Results
-- New ASA initiatives to advance education and innovation for the anesthesia community -- -- PDUFA action date for EXPAREL as a lower extremity nerve block on track for November 13, 2023 --
![](https://cdn.snapi.dev/images/v1/3/a/conf1-2122425.jpg)
Pacira to Report Third Quarter 2023 Financial Results on Thursday November 2, 2023
TAMPA, Fla., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its third quarter financial results before the open of the U.S. markets on Thu...
![](https://cdn.snapi.dev/images/v1/r/r/press6-2100425.jpg)
American Society of Anesthesiologists Announces New Industry Supporter Pacira BioSciences, Inc.
SCHAUMBERG, Ill. and TAMPA, Fla., Oct. 12, 2023 (GLOBE NEWSWIRE) -- The American Society of Anesthesiologists (ASA) today announced Pacira BioSciences, Inc. (Nasdaq: PCRX) has joined ASA's Industry Su...
![](https://cdn.snapi.dev/images/v1/q/i/press8-2096547.jpg)
Pacira BioSciences Appoints Four New Independent Directors to its Board of Directors
-- Enhances diversity and expertise in key areas including scientific, commercial, and financial -- TAMPA, Fla., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry...
![](https://cdn.snapi.dev/images/v1/v/j/press14-2085575.jpg)
American Society of Anesthesiologists and Pacira BioSciences, Inc. Announce New Grant to Advance Education and Enhance Patient Care
SCHAUMBURG, Ill. and TAMPA, Fla., Oct. 02, 2023 (GLOBE NEWSWIRE) -- The American Society of Anesthesiologists (ASA) and Pacira BioSciences, Inc. (Nasdaq: PCRX), today announced a new grant of $2.5 mil...